Adage Capital Partners
FULC icon

Adage Capital Partners’s Fulcrum Therapeutics FULC Stock Holding History

Adage Capital Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.32M Buy
2,000,000
+1,600,000
+400% +$9.73M 0.01% 765
2026
Q1 		$3.07M Sell
400,000
-1,300,000
-76% -$12.1M ﹤0.01% 813
2025
Q4 		$19.2M Sell
1,700,000
-732,000
-30% -$7.45M 0.03% 494
2025
Q3 		$22.4M Sell
2,432,000
-2,157,000
-47% -$15.6M 0.04% 431
2025
Q2 		$31.6M Buy
4,589,000
+1,589,000
+53% +$8.5M 0.05% 335
2025
Q1 		$8.64M Hold
3,000,000
– – 0.02% 615
2024
Q4 		$14.1M Buy
3,000,000
+1,000,000
+50% +$3.69M 0.02% 525
2024
Q3 		$7.14M Buy
2,000,000
+1,700,000
+567% +$12.6M 0.01% 673
2024
Q2 		$1.86M Sell
300,000
-806,422
-73% -$6.11M ﹤0.01% 784
2024
Q1 		$10.4M Sell
1,106,422
-400,000
-27% -$3.57M 0.02% 590
2023
Q4 		$10.2M Sell
1,506,422
-900,000
-37% -$3.99M 0.02% 588
2023
Q3 		$10.7M Buy
2,406,422
+100,000
+4% +$437K 0.02% 547
2023
Q2 		$7.61M Buy
2,306,422
+500,000
+28% +$1.47M 0.02% 617
2023
Q1 		$5.15M Buy
1,806,422
+686,422
+61% +$6.15M 0.01% 705
2022
Q4 		$8.15M Sell
1,120,000
-200,000
-15% -$1.3M 0.02% 685
2022
Q3 		$10.7M Buy
1,320,000
+1,050,000
+389% +$7.52M 0.03% 619
2022
Q2 		$1.32M Sell
270,000
-1,680,000
-86% -$16.4M ﹤0.01% 909
2022
Q1 		$46.1M Buy
1,950,000
+230,000
+13% +$3.26M 0.09% 233
2021
Q4 		$30.4M Buy
1,720,000
+540,000
+46% +$10.7M 0.05% 343
2021
Q3 		$33.3M Buy
+1,180,000
New +$22.4M 0.07% 302

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's FULC Position: Q2 2026 in Review

Adage Capital Partners increased its Fulcrum Therapeutics (FULC) stake by 400% in Q2 2026, buying an estimated $9.73M and bringing the position to 2,000,000 shares worth $7.32M. The position accounts for 0.01% of the portfolio, ranked #765.

Adage Capital Partners first reported a position in FULC in Q3 2021 and has held it in 20 quarters since. The position peaked at $46.1M in Q1 2022. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Adage Capital Partners held 2,000,000 shares of Fulcrum Therapeutics worth $7.32M as of Q2 2026.
  • Adage Capital Partners bought 1,600,000 Fulcrum Therapeutics shares in Q2 2026, an estimated $9.73M.
  • Fulcrum Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #765 holding.
  • Adage Capital Partners first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Adage Capital Partners's Fulcrum Therapeutics position peaked at $46.1M in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.